Overview

Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)

Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The primary objective was to assess the effect of Xepol compared to placebo on physical health and on muscle strength in subjects with post-polio syndrome.The secondary objective was to assess the effect of Xepol compared to placebo on functional balance, activity patterns, pain, fatigue, sleep, vitality, muscular strength, pulmonary capacity, walking ability, balance and safety.
Phase:
N/A
Details
Lead Sponsor:
Calliditas Therapeutics AB
Pharmalink AB
Treatments:
Antibodies
Immunoglobulins